Biosimilar Development Meetings At US FDA Not Just For Talking Similarity
Executive Summary
Sponsors shouldn't wait until pre-submission meetings with the agency to discuss manufacturing, packaging and other matters unrelated to similarity data, FDA's Leah Christl says in remarks seemingly aimed at calling attention to issues that can forestall approval.
You may also be interested in...
Insulin Applications Intended For Biosimilar Pathway May Already Be At US FDA
In congressional testimony, outgoing Commissioner Scott Gottlieb says FDA already has "a lot of applications in-house" and robust interest when asked about the 2020 transition of insulin from regulation as a drug to a biologic.
US FDA's Biosimilars Program: Five Years In, Complete Response Letters Still Outnumber Approvals
Agency is meeting its review timelines for biosimilar applications but handing our more complete response letters than first-cycle approvals; sponsors have publicly disclosed 24 original biosimilar application submissions to the agency since the review program began in fiscal year 2013, with 10 product approvals to date and at least 13 CRLs, according to the Pink Sheet's biosimilars report card.
US FDA's Biosimilars Program: Five Years In, Complete Response Letters Still Outnumber Approvals
Agency is meeting its review timelines for biosimilar applications but handing our more complete response letters than first-cycle approvals; sponsors have publicly disclosed 24 original biosimilar application submissions to the agency since the review program began in fiscal year 2013, with 10 product approvals to date and at least 13 CRLs, according to the Pink Sheet's biosimilars report card.